CN103096901A - 眼用组合物 - Google Patents

眼用组合物 Download PDF

Info

Publication number
CN103096901A
CN103096901A CN2011800332340A CN201180033234A CN103096901A CN 103096901 A CN103096901 A CN 103096901A CN 2011800332340 A CN2011800332340 A CN 2011800332340A CN 201180033234 A CN201180033234 A CN 201180033234A CN 103096901 A CN103096901 A CN 103096901A
Authority
CN
China
Prior art keywords
dorzolamide
timolol
test
ophthalmic composition
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800332340A
Other languages
English (en)
Chinese (zh)
Inventor
井上淳
T.沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju USA Inc
Original Assignee
Senju USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju USA Inc filed Critical Senju USA Inc
Publication of CN103096901A publication Critical patent/CN103096901A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2011800332340A 2010-05-05 2011-05-04 眼用组合物 Pending CN103096901A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/774,419 2010-05-05
US12/774,419 US8211450B2 (en) 2010-05-05 2010-05-05 Ophthalmic composition
PCT/US2011/035147 WO2011140194A1 (en) 2010-05-05 2011-05-04 Ophthalmic composition

Publications (1)

Publication Number Publication Date
CN103096901A true CN103096901A (zh) 2013-05-08

Family

ID=44902332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800332340A Pending CN103096901A (zh) 2010-05-05 2011-05-04 眼用组合物

Country Status (8)

Country Link
US (2) US8211450B2 (OSRAM)
EP (1) EP2566487A4 (OSRAM)
JP (1) JP2013528589A (OSRAM)
KR (1) KR20130121685A (OSRAM)
CN (1) CN103096901A (OSRAM)
CA (1) CA2797123A1 (OSRAM)
MX (1) MX2012012846A (OSRAM)
WO (1) WO2011140194A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103740831A (zh) * 2014-01-13 2014-04-23 宁波海尔施基因科技有限公司 一种指导β-受体阻断药用药的引物组合物、多重基因检测试剂盒及其使用方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013001116A (es) * 2010-07-29 2013-06-05 Santen Pharma Co Ltd Cuerpo para soporte de farmaco, y metodo para producir el mismo.
WO2013114397A2 (en) * 2012-01-16 2013-08-08 Biocon Limited Pharmaceutically acceptable salt of brinzolamide and composition thereof
US9820991B2 (en) * 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
EP3096740B1 (en) * 2014-01-24 2020-09-30 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
EP3142993B2 (en) * 2014-05-16 2022-01-12 Occidental Chemical Corporation Method for making 1,1,3,3-tetrachloropropene
JP6373995B2 (ja) * 2014-07-11 2018-08-15 富士フイルム株式会社 眼科用水性組成物
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
KR101773669B1 (ko) 2015-07-30 2017-08-31 포항공과대학교 산학협력단 생체적합성 각막세포 전구체 분화방법 및 각막세포 전구체 조성물
JP6050454B1 (ja) * 2015-09-28 2016-12-21 参天製薬株式会社 水性医薬組成物
JP6178028B1 (ja) * 2016-03-14 2017-08-09 参天製薬株式会社 ドルゾラミドとチモロールと界面活性剤を含有する医薬組成物
KR20200111177A (ko) 2017-12-15 2020-09-28 타르서스 파마수티칼스, 아이엔씨. 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
US20220265695A1 (en) 2019-07-26 2022-08-25 Proqr Therapeutics Ii B.V. Opthalmic compositions comprising viscosifying polymers and nucleic acids
CN118613267A (zh) 2022-01-21 2024-09-06 千寿美国有限公司 水性液体制剂
CN118978426B (zh) * 2024-10-22 2025-05-16 浙江大学 一种甘油的酸化处理方法、酸化甘油及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204472A1 (en) * 2003-02-13 2006-09-14 Constantinos Paleos Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems
US20070048337A1 (en) * 2005-08-24 2007-03-01 Arthur Samuel D Aldol-crosslinked polymeric hydrogel adhesives
US20080180803A1 (en) * 2007-01-26 2008-07-31 Seybert Kevin W Optical elements comprising compatiblizing coatings and methods of making the same
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136014A (en) * 1990-06-22 1992-08-04 E. I. Du Pont De Nemours And Company Hyperbranched polyesters
SK282039B6 (sk) * 1991-04-17 2001-10-08 Merck & Co., Inc. Oftalmický prípravok na liečenie očnej hypertenzie obsahujúci kombináciu inhibítora karboanhydrázy a beta-adrenergného antagonistu
US6316443B1 (en) * 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
FR2772771B1 (fr) * 1997-12-19 2000-01-28 Oreal Utilisation de polymeres hyperbranches et de dendrimeres comportant un groupement particulier, en tant qu'agent filmogene, les compositions filmogenes les comprenant et leur utilisation notamment en cosmetique ou en pharmacie
WO2000063409A1 (en) 1999-04-21 2000-10-26 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
US7097856B2 (en) 2000-09-29 2006-08-29 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
CA2438193A1 (en) 2001-02-26 2002-09-06 Duke University Novel dendritic polymers and their biomedical uses
AU2002304314B2 (en) 2001-03-08 2007-09-06 Nyomox Pharmaceutical Corporation Using neural thread proteins to treat tumors and other hyperproliferative disorders
FR2830450B1 (fr) 2001-10-09 2004-02-06 Univ Pasteur Utilisation de dendrimeres dans une composition ophtalmique
AR038269A1 (es) 2002-01-09 2005-01-12 Novartis Ag Articulos polimericos que tienen un recubrimiento lubrico, y metodo para fabricarlos
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
JP2005008614A (ja) 2003-03-28 2005-01-13 Nano Career Kk 高分子ミセルを用いた眼科用ドラッグデリバリーシステム
US7109247B2 (en) 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7189456B2 (en) 2004-03-04 2007-03-13 Transitions Optical, Inc. Photochromic optical article
WO2006031358A2 (en) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US7837986B2 (en) 2004-12-01 2010-11-23 E. I. Du Pont De Nemours And Company Protein-based polymer tissue adhesives for medical use
WO2006087227A2 (de) * 2005-02-21 2006-08-24 Basf Aktiengesellschaft Wirkstoffzusammensetzung die wenigstens ein stickstoffatomhaltiges hyperverweigtes polymer enthält
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US7666331B2 (en) 2005-08-31 2010-02-23 Transitions Optical, Inc. Photochromic article
AU2006336176B2 (en) 2006-01-20 2013-08-22 Starpharma Pty Limited Modified macromolecule
WO2008054466A2 (en) 2006-03-03 2008-05-08 Dendritic Nanotechnologies, Inc. Delivery of biologically active materials using core-shell tecto (dendritic polymers)
US20080031916A1 (en) * 2006-04-24 2008-02-07 Heather Sheardown Dendrimer cross-linked collagen
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
US20090324742A1 (en) 2006-09-08 2009-12-31 Sonke Svenson Peham dendrimers as excipients
MX2009004856A (es) * 2006-11-09 2009-06-05 Alcon Res Ltd Matriz polimerica insoluble en agua para suministro de farmaco.
WO2009046446A2 (en) * 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
WO2009064963A2 (en) 2007-11-14 2009-05-22 E. I. Du Pont De Nemours And Company Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
WO2010017184A2 (en) * 2008-08-08 2010-02-11 Virginia Commonwealth University Dendrimer hydrogels

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204472A1 (en) * 2003-02-13 2006-09-14 Constantinos Paleos Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems
US20070048337A1 (en) * 2005-08-24 2007-03-01 Arthur Samuel D Aldol-crosslinked polymeric hydrogel adhesives
US20080180803A1 (en) * 2007-01-26 2008-07-31 Seybert Kevin W Optical elements comprising compatiblizing coatings and methods of making the same
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103740831A (zh) * 2014-01-13 2014-04-23 宁波海尔施基因科技有限公司 一种指导β-受体阻断药用药的引物组合物、多重基因检测试剂盒及其使用方法

Also Published As

Publication number Publication date
US20110275617A1 (en) 2011-11-10
WO2011140194A1 (en) 2011-11-10
EP2566487A4 (en) 2014-06-18
EP2566487A1 (en) 2013-03-13
KR20130121685A (ko) 2013-11-06
JP2013528589A (ja) 2013-07-11
CA2797123A1 (en) 2011-11-10
US20130053374A1 (en) 2013-02-28
MX2012012846A (es) 2013-05-22
US8211450B2 (en) 2012-07-03

Similar Documents

Publication Publication Date Title
CN103096901A (zh) 眼用组合物
Ren et al. Encapsulation of azithromycin ion pair in liposome for enhancing ocular delivery and therapeutic efficacy on dry eye
EP2763654B1 (en) Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid
IL310360A (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
CN107847432A (zh) D2o稳定化的药物制剂
JP2004528267A (ja) 選択的シクロオキシゲナーゼ−２阻害性薬物の眼処方
WO2010059894A1 (en) Ocular formulations of norketotifen
US12397000B2 (en) Stabilized ophthalmic dexamethasone compositions
JPH08503951A (ja) シクロデキストリンとポリマーを用いた薬剤供給系
Ricci et al. Chitosan/sulfobutylether-β-cyclodextrin based nanoparticles coated with thiolated hyaluronic acid for indomethacin ophthalmic delivery
CN111727035A (zh) 包含比拉斯汀、β-环糊精和至少一种胶凝剂的眼用组合物
Fang et al. Nanoemulsion-based pseudopolyrotaxane hydrogel for enhanced corneal bioavailability and treatment of corneal inflammation
WO2024139728A1 (zh) 一种低聚集体眼用纳米制剂及其制备方法和用途
WO2006117666A2 (en) Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
Lorenzo Veiga Cyclodextrin nanostructures and ocular drug delivery
Acharya Development and Evaluation of Liquid Crystalline Cubogel for Ocular Delivery of Anti-glaucoma Agents
CN121197364A (zh) 一种中西药协同作用的无载体纳米粒及其制备方法和应用
Masareddy et al. Development of Bimatoprost-Loaded Nano Spanlastic In-Situ Gel for Ophthalmic Drug Delivery: A Box-Behnken Optimization Approach with In Vitro and Ex Vivo Characterization
US20230218611A1 (en) Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
CN120583950A (zh) 含二氟泼尼酯的水性纳米胶束眼用制剂
Maw Development of cyclodextrin-based pickering nanoemulsion containing amphotericin b for treatment of fungal keratitis
US20250387411A1 (en) Ph stabilized ophthalmic compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130508